Top Back to top

EBMT Research

by Mohamad Mohty
Research

Over the last few months, the focus of the different Working Parties remains unwavering on delivering cutting edge practical data and transplant guidelines. This focus is mainly based on the real-life experience gathered within the EBMT registry, as well as on the optimal management of transplant patients, especially with the advent of numerous targeted therapies which are being used before and after transplantation (e.g. ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with CLL or mantle cell lymphoma; brentuximab vedotin prior and/or after allogeneic stem cell transplantation in Hodgkin lymphoma). The haplo-identical transplant approach continues to be an ever-evolving strategy that has been experiencing an impressive boom, particularly in acute leukaemia. It is already proving to be a valid transplant modality with outcomes similar to those achieved with other stem cell sources and donors (e.g. unmanipulated haploidentical versus matched sibling donor in patients with AML in CR1; haploidentical versus unrelated allogeneic stem cell transplantation for relapsed/refractory AML, etc.).

At the same time, the EBMT registry is a timeless gateway to investigating the role of stem cell transplantation in rare disease entities or complications (e.g. IPEX syndrome, transplant-associated microangiopathy, outcome of patients receiving salvage third autologous stem cell transplantation in multiple myeloma, donor cell-derived leukaemia/MDS following stem cell transplantation, etc.)

The EBMT is committed to generating novel and important research data, and always does so under the premise of continuous evaluation of transplant practices (e.g. activity survey on the use of unrelated donor transplantation), incorporation of the latest technological advances into the field (e.g. development of the eGVHD app in assessing the severity of GVHD), and close collaboration with other sister societies (e.g. role of autologous stem cell transplantation in severe Crohn's disease).

Need help?

The personal data provided will be processed according to the General Data Protection Regulation (GDPR 2016/679 ) and incorporated to a file property of EBMT which will be allocated in the EEA (European Economic Area) or in countries that are provided with the same level of protection for privacy such as countries that adhere to EU-US and Swiss-US Privacy Shield Frameworks.
Data Subjects have the right of access to his or her data and the right to rectification of any inaccurate or incomplete personal data. The Data Subject also has the right to withdraw consent, this wish will be respected, and the personal will no longer be made available. If the processing operation is unlawful the Data Subject has the right to request deletion of that data. Please write to data.protection@ebmt.org